You can buy or sell Cytosorbents and other stocks, options, ETFs, and crypto commission-free!
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. Read More The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Monmouth Junction, New Jersey
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 9
CTSO: Distributor Sales Take a Breather But Expected to Rebound. Direct Sales Remain Robust
By Brian Marckx, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Q1 2019 Update: Distributor Sales Take a Breather But Expected to Rebound. Direct Sales Remain Robust… CytoSorbents (CTSO) reported financial results for their first quarter ending March 31st and provided a business update. While grant revenue was inline with expectations, product sales were a relative dud. While up 3% yoy, product sales fell 16% sequentially as three of the company’s most significant distributors significantly ...
Seeking AlphaMay 7
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2019 Results - Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2019 Earnings Conference Call May 7, 2019 4:45 PM ET Company Participants Jeremy Feffer - IR, LifeSci Advisors Phillip Chan - CEO and President Vincent Capponi - COO Kathleen Bloch - CFO Eric Mortensen - Chief Medical Officer Christian Steiner - SVP of Sales and Marketing Christopher Cramer - VP of Business Development Conference Call Participants Andrew D'Silva - B. Riley FBR Jason McCarthy - Maxim Group Brian Marckx - Zacks Investment Research Operato...
PR NewswireMay 7
CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance
MONMOUTH JUNCTION, N.J., May 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending March 31, 2019. First Quarter 2019 Financial Results: Total revenue for Q1 2019 was $5.2 million , including both product sales and grant income, compared to $4.9 million...
Expected Aug 1, After Hours